English  |  正體中文  |  简体中文  |  0  
???header.visitor??? :  52582411    ???header.onlineuser??? :  783
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"lin z z"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 221-245 of 330  (14 Page(s) Totally)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2020-05-25T07:35:05Z Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients Yu C.-J.;Yang J.C.-H;Chia-Chi Lin;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.-H; Yu C.-J.
臺大學術典藏 2020-05-25T06:52:07Z Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma Wang Y.-C; Wang D; Hung J.-H; Tang M; Lin Z.-Z; Chen T.-J; Cheng A.-L; Chen C.-S.; Yen-Shen Lu;Kashida Y;Kulp S.K;Wang Y.-C;Wang D;Hung J.-H;Tang M;Lin Z.-Z;Chen T.-J;Cheng A.-L;Chen C.-S.; YEN-SHEN LU; Kashida Y; Kulp S.K
臺大學術典藏 2020-05-25T06:51:58Z The impact of diabetes mellitus on prognosis of early breast cancer in Asia Lai M.-S.;Cheng A.-L;Kuo R.N.C;Chen H.-M;Yen-Shen Lu;Lin Z.-Z;Shau W.-Y;Shao Y.-Y;Chen W.-W; Chen W.-W; Shao Y.-Y; Shau W.-Y; Lin Z.-Z; YEN-SHEN LU; Chen H.-M; Kuo R.N.C; Cheng A.-L; Lai M.-S.
臺大學術典藏 2020-05-25T06:51:58Z Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma Cheng A.-L.;Hsu C.-H;Shen Y.-C;Huang C.-C;Yen-Shen Lu;Hsiao C.-H;Lee K.-D;Hsu C;Lin Z.-Z;Shao Y.-Y; Shao Y.-Y; Lin Z.-Z; Hsu C; Lee K.-D; Hsiao C.-H; YEN-SHEN LU; Huang C.-C; Shen Y.-C; Hsu C.-H; Cheng A.-L.
臺大學術典藏 2020-05-25T02:45:35Z The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases Chiang Y; Yang J.C.-H; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y; Lin Z.-Z; Lan K.-H; Cheng A.-L; Kuo S.-H.
臺大學術典藏 2020-05-25T01:32:58Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-05-20T05:11:42Z Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-05-20T04:46:48Z Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status MING-CHIN YANG; Lin Z.-Z.; Liao C.-H.; Tan E.C.-H.; Chen H.-C.; Ming-Chin Yang;Lin Z.-Z.;Liao C.-H.;Tan E.C.-H.;Chen H.-C.
臺大學術典藏 2020-04-28T07:25:39Z Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Yeh K.-H.;Wang C.-H.;Chih-Hung Hsu;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; Yeh K.-H.; Wang C.-H.; CHIH-HUNG HSU; Liu M.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:30Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.; CHIH-HUNG HSU; Yu C.-J.; Chang Y.-C.; Hsu C.; Yang C.-H.;Yang P.-C.;Cheng A.-L.;Lin C.-C.;CHIH-HUNG HSU;Yu C.-J.;Chang Y.-C.;Hsu C.;Lin Z.-Z.; Lin Z.-Z.
臺大學術典藏 2020-04-28T07:25:28Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.; Shen Y.-C.; CHIH-HUNG HSU; Chih-Hung Hsu;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Hsu C.;Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:28Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Chih-Hung Hsu;Yang T.-S.;Hsu C.;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; CHIH-HUNG HSU; Yang T.-S.; Hsu C.; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:27Z Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma Shao Y.U.-Y. ;Chen P.-J. ;Lin Z.-Z. ;Huang C.-C. ;Ding Y.-H. ;Lee Y.-H. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.U.-Y.; Chen P.-J.; Lin Z.-Z.; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:27Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.;Lin Z.-Z.;Hsu C.;Shen Y.-C.;Chih-Hung Hsu;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:25Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Hsu C. ;Shen Y.-C. ;Chih-Hung Hsu ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Shen Y.-C.; CHIH-HUNG HSU; Cheng A.-L.
臺大學術典藏 2020-04-28T07:25:13Z Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C.
臺大學術典藏 2020-04-28T07:25:08Z A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chih-Hung Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; CHIH-HUNG HSU; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏 2020-04-10T12:51:23Z Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment Yang C.-H.; Yang P.-C.; Cheng A.-L.; Lin C.-C.; Hsu C.-H.; Yu C.-J.; Chang Y.-C.; Chiun Hsu; Lin Z.-Z.
臺大學術典藏 2020-04-10T12:51:22Z Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival Cheng A.-L.; Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Chiun Hsu
臺大學術典藏 2020-04-10T12:51:21Z The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Kuo S.-H.;Chiun Hsu;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; Kuo S.-H.; Chiun Hsu; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:20Z Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma Hsu C.-H.;Yang T.-S.;Chiun Hsu;Toh H.C.;Epstein R.J.;Hsiao L.-T.;Chen P.-J.;Lin Z.-Z.;Chao T.-Y.;Cheng A.-L.; Hsu C.-H.; Yang T.-S.; Chiun Hsu; Toh H.C.; Epstein R.J.; Hsiao L.-T.; Chen P.-J.; Lin Z.-Z.; Chao T.-Y.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:19Z Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma Hsu C.-H.;Shen Y.-C.;Lin Z.-Z.;Chen P.-J.;Shao Y.-Y.;Ding Y.-H.;Chiun Hsu;Cheng A.-L.; Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Chiun Hsu; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:17Z Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Shao Y.-Y.;Lin Z.-Z.;Chiun Hsu;Shen Y.-C.;Hsu C.-H.;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:16Z High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy Shao Y.-Y. ;Lin Z.-Z. ;Chen T.-J. ;Chiun Hsu ;Shen Y.-C. ;Hsu C.-H. ;Cheng A.-L.; Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Chiun Hsu; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏 2020-04-10T12:51:15Z Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y.

Showing items 221-245 of 330  (14 Page(s) Totally)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
View [10|25|50] records per page